Abstract
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have